Marathon Pharmaceuticals

Athersys Appoints Joseph Nolan to Its Board of Directors

Retrieved on: 
Thursday, January 5, 2023

Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Joseph “Joe” Nolan to its Board of Directors, effective January 4, 2023.

Key Points: 
  • Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Joseph “Joe” Nolan to its Board of Directors, effective January 4, 2023.
  • Mr. Nolan is an experienced biotechnology and pharmaceutical executive who currently serves as Chief Executive Officer of Jaguar Gene Therapy, LLC.
  • With this appointment, Athersys has five Directors, four of whom are independent.
  • “I’m proud to join the Athersys Board and am enthusiastic about MultiStem’s potential across a range of unmet medical needs.

Acasti Pharma Appoints Healthcare Industry Leader Michael L. Derby to its Board of Directors

Retrieved on: 
Friday, March 25, 2022

Mr. Derby brings more than two decades of experience and a proven track record within the biopharmaceutical industry with particular expertise in strategic drug repurposing. Having founded or co-founded seven biopharmaceutical companies, he most recently launched TardiMed Sciences LLC, a company creation and investment firm in the life sciences space. TardiMed has formed, capitalized and advanced three biopharmaceutical companies -- Timber Pharmaceuticals, Inc. (NYSE:TMBR), PaxMedica, Inc. and Anker Pharmaceuticals LLC -- through Phase 2 clinical trials. Mr. Derby served as Executive Chairman of the Board of Directors for all three companies. Prior to TardiMed, Mr. Derby co-founded Castle Creek Pharmaceuticals, which he built into a multi-product, late clinical stage company focused on treating rare and debilitating dermatologic conditions. He also founded Norphan Pharmaceuticals, a biopharmaceutical company focused on the development of drugs for orphan neurologic disease, which he led through its early stages prior to selling the company to Marathon Pharmaceuticals. Prior to founding and managing life sciences companies, Mr. Derby was with an early-stage private equity and investment advisory firm, Centerstone Partners, and was a venture capitalist with EGS Healthcare Capital Partners. Mr. Derby holds an M.B.A., with distinction, from New York University’s Stern School of Business, an M.S. in Neuroscience from the University of Rochester, and a B.S., with honors, from Johns Hopkins University, where he was a Beneficial Hodson merit scholar and member of the Tau Beta Pi engineering honor society.

Key Points: 
  • LAVAL, Quebec, March 25, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST) today announces that it has appointed Michael L. Derby to its Board of Directors.
  • Mr. Derby brings more than two decades of experience and a proven track record within the biopharmaceutical industry with particular expertise in strategic drug repurposing.
  • Mr. Derby served as Executive Chairman of the Board of Directors for all three companies.
  • Acasti is an advanced-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases.

Avelas makes senior appointments and provides update on pegloprastide Phase III clinical program

Retrieved on: 
Monday, October 18, 2021

Ms. Sheriff is an expert in global regulatory strategies with more than 32 years of regulatory affairs and product development experience.

Key Points: 
  • Ms. Sheriff is an expert in global regulatory strategies with more than 32 years of regulatory affairs and product development experience.
  • In addition to his role at Avelas, he is a Senior Advisor and Capital Markets Lead at MHA MacIntyre Hudson.
  • Through the benefits of Breakthrough Therapy Designation, Avelas has continued to collaborate with the FDA on the design of the Companys registrational confirmatory Phase III trial.
  • Following this constructive dialogue with the FDA, we are excited to continue the clinical development of this exciting candidate.

Global Orphan Assets Market Trends & Outlook Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 16, 2021

The "Market Trends for Orphan Assets: A Global Outlook" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Trends for Orphan Assets: A Global Outlook" report has been added to ResearchAndMarkets.com's offering.
  • 'Orphan drugs' are intended to treat rare/ultra rare diseases.
  • They are developed to treat patients suffering from very serious diseases for which no treatment, or adequate one, is available.
  • Rare disease patient populations in key launch markets are defined in law as:

New Report Finds Medical Treatments for Rare Diseases Account for Only 11% of US Drug Spending; Nearly 80% of Orphan Products Treat Rare Diseases Exclusively

Retrieved on: 
Thursday, March 4, 2021

The report alsohighlights recent progress in drug development that has resulted in more people with rare diseases having access to critical treatments.

Key Points: 
  • The report alsohighlights recent progress in drug development that has resulted in more people with rare diseases having access to critical treatments.
  • As of January 1, 2020,564orphanproductswere approved by the US Food and Drug Administration (FDA) to treat 838 rare diseases (or "indications").
  • "People with rare diseases need help, and the Orphan Drug Act is important for spurring innovation."
  • NORD commissions the study every two years to examine the state of drug development for rare diseases as part of its mission to support people with rare diseases.

Immunoforge's 'PF1801' Is Designated as Orphan Drug by FDA

Retrieved on: 
Thursday, January 28, 2021

SEOUL, South Korea, Jan. 28, 2021 /PRNewswire/ -- Immunoforge, the company specializing in the development of new drugs for rare musculoskeletal diseases (Representatives: An Seong-Min and Jang Gi-Ho), announced that their new drug candidate PF1801 has been designated as the FDA orphan drug for treatment of the Duchenne muscular dystrophy on January 25.

Key Points: 
  • SEOUL, South Korea, Jan. 28, 2021 /PRNewswire/ -- Immunoforge, the company specializing in the development of new drugs for rare musculoskeletal diseases (Representatives: An Seong-Min and Jang Gi-Ho), announced that their new drug candidate PF1801 has been designated as the FDA orphan drug for treatment of the Duchenne muscular dystrophy on January 25.
  • As the orphan drug designation awardee, Immunoforge will be granted the following benefits from the FDA: waiver of qualified clinical trials costs and FDA expedited review during clinical trials for the Duchenne muscular dystrophy, as well as 7-years of exclusive right on marketing upon market approval.
  • Immunoforge plans to obtain approval from the US FDA for phase 2 clinical trials of the Duchenne muscular dystrophy and promote clinical trials in the second half of 2021, thus it has established a branch office in the United States.
  • It aims to grow into a global company like Alexion in the field of rare musculoskeletal diseases.

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Type & Geography (2019-2023) - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 10, 2019

The "Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023" report has been added to ResearchAndMarkets.com's offering.
  • The Duchenne muscular dystrophy (DMD) therapeutics market analysis considers sales from both biologics and small molecules in Asia, Europe, North America, and RoW.
  • Also, our global DMD therapeutics market report looks at factors such as high unmet need, increasing strategic alliance, and patient assistance programs.
  • With the presence of a few major players, the global Duchenne muscular dystrophy (DMD) therapeutics market is highly concentrated.

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market 2019-2023 | Patient Assistance Programs to Boost Growth | Technavio

Retrieved on: 
Wednesday, September 4, 2019
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190904005405/en/
    Technavio has announced its latest market research report titled global Duchenne muscular dystrophy (DMD) therapeutics market 2019-2023.
  • In addition, patient assistance programs are anticipated to further boost the Duchenne muscular dystrophy (DMD) therapeutics market during the forecast period.
  • This creates significant opportunity for vendors to enter the global DMD therapeutics market to cater to the high unmet demand.
  • Furthermore, various governments have come up with patient assistance programs to help reduce the cost burden associated with these therapeutics.